Case File
efta-efta01385523DOJ Data Set 10CorrespondenceEFTA Document EFTA01385523
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01385523
Pages
0
Persons
0
Integrity
Loading PDF viewer...
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
> Energy, Materials & Industrials
DSM - Virginie Boucher-Ferte, BUY, close €81.8, €100 tgt, 22% potential upside
• We see Nutrition (68% of EBITDA) as a key growth driver. We forecast a
9% EBITDA 2018-20E CAGR driven by cost cutting, innovation and
leverage of its broad portfolio.
- A greater proportion of the Nutrition portfolio is in higher-value and
faster-growing ingredients and 'solutions' rather than just vitamins.
• Up to 30% upside to 18E EBITDA forecast if vitamin price increases are
sustained.
- Prices are unlikely to revert fully: China's environmental policies are
should give structural support in the long term.
■ Full exit from Materials likely, driving portfolio shift towards becoming a
pure play in higher-value ingredients.
■ M&A should drive the next phase of development. DSM is likely to use its
strong balance sheet (0.5x 17E net debt/EBITDA) to broaden its
ingredients portfolio.
Deutsche Bank Gil
DSM Nutrition organic growth now compares well to peers
10%
9%
8%
7%
6%
5%
4%
3%
2%
1%
0%
• •
I
DSM Nutntion organic growth
— — Food Ingredients organic growth average
2009
2010
2011
2012
2013
2014
2015
2016
2017E
Lots of firepower for accretive M &A (DBe synergies 6% of sales)
- This would unlock >E20/share of value from EPS accretion and re-
3000
rating.
• Trades on 16x 19E PIE, in line with chems but a 33% discount to
2
ingredients. We believe the portfolio shift should prompt re-rating.
15000
■ Our €100 tgt implies a 20x 19E PIE — still a 15% discount to ingredients.
1000
• Catalysts: Upside through higher value and fast growing ingredients and
500 -
"solutions". Portfolio shift optionality.
Related DB Research:
-500
()SPA: The path to E100 (and potentially more): upgrade to BUY (Boucher-Fenel
nI gredients: 2018 Outlook: Recipe for successi_Boucher-Fertel
2500 -
Net Debt (LHS)
2007
2009
2011
—Net Deb/EBITDA (RHS)
2013
2015
2017E
2019E
2.50
2.00
1.50
1.00
0.50
0.00
-0.50
:),,ean Equity Focus -January 2018
CONFIDENTIAL - PURSUANT TO FED. R. GRIM. P. 6(e)
CONFIDENTIAL
DB-SDNY-0086809
SDNY_GM_00232993
EFTA01385523
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.